First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Moleculin Biotech, Inc.

    MBRX · 3 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 3 macro, policy, and market developments to Moleculin Biotech, Inc. since 2026-09-23. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for MBRX yet, so no modelled value is shown. The MBRX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run MBRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for MBRX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial

      Clinical trial progress reduces development risk and moves closer to potential commercialization. Enrollment completion is a key de-risking milestone.

      · Moves probability of technical success (pts) for annamycin, time to market for annamycin, future revenue projections for annamycin

    What changed, by assumption

    Probability of technical success (pts) for annamycin
    • 2026-09-29Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial
    Probability of technical success (pots) for annamycin
    • 2026-09-25Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR
    Probability of success for annamycin in lung indications
    • 2026-09-23Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-25Share countBullishCompany explicitly states it requires significant additional financing to conduct clinical trials, which typically results in equity dilution for biotech firms at this stage.0.85

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE TrialBullish3-12m0.80
    2026-09-25Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACRBullish1-3m0.80
    2026-09-23Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040Bullish1-5y0.70